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Background
Chronic hepatitis is an important problem worldwide,
associating high morbidity and mortality, and hepatocel-
lular-carcinoma is one of its most severe complications.
Multiple studies have tried to identify biomarkers that
would allow an earlier detection of hepatocellular-
carcinoma (HCC), compared to imagistic exams. Such bio-
markers are represented by alpha-fetoprotein (AFP), des-g-
carboxy prothrombin (DPC), and the lens culinaris agglu-
tinin-reactive fraction of alpha-fetoprotein (AFP-L3).
Methods
Since January 2014, the National Institute for Infectious
Diseases “Prof. Dr. Matei Balş” has implemented a
screening program for hepatocellular carcinoma in
patients with hepatitis. The program involves a serum
panel performed in the Lotus-MED Medical Center,
consisting of AFP, DCP and AFP-L3%, performed at
two study visits: screening and 48 weeks follow-up. As
the study is still ongoing, we present descriptive data
derived from the first study visit.
Results
We have enrolled 120 patients; their mean age was 56.6
± 12.2 years, and the male-to-female ratio was 1.07:1.
The patients were diagnosed with chronic hepatitis B
(8.8%), chronic hepatitis C (72.5%), B+D coinfection
(9.9%), idiopathic hepatitis (4.4%) and other causes of
liver disease (4.4%). Only 65% of patients had cirrhosis,
and 8% of them had a diagnosis of hepatocellular-
carcinoma.
The mean values for the serum panel tests were
158.95 ± 1419.82 ng/mL (AFP), 11.68±59.20 ng/mL
(DCP), and 14.83±21.85% (AFP-L3%).
In the group of patients with cirrhosis, the positive pre-
diction for HCC based on the serum panel tests was
32.20%. 23.53% of the persons with positive prediction
already had a diagnosis of HCC, while 92.5% of the per-
sons with negative prediction did not have a history of
HCC. The test’s sensitivity for predicting HCC was
57.14%, and its specificity was 74%. The positive predictive
value (PPV) was 23.53% and the negative predictive value
(NPV) 92.5%.
Conclusion
Our preliminary results represent the first serum panel
predictions for HCC in the population of Romanian
patients with chronic hepatitis. However, given the fact
that only 65% of patients displayed cirrhosis at the time
of testing, the analysis has also been applied outside of its
validated range, and we can only rely on the data avail-
able for patients with cirrhosis. The patients will be rein-
vestigated at 48 weeks, and only then will we be able to
calculate an accurate sensitivity, specificity, PPV or NPV,
as this serum test is thought to predict a patient’s prob-
ability of developing HCC over the next 6 months.
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